My IGF-1 increased. Does that mean sermorelin is helping?

A changed number answers only part of the question

An IGF-1 increase can be meaningful to the clinician monitoring a treatment, but it does not establish that the outcome you wanted has improved. The useful follow-up has two parts: what the laboratory change means medically, and whether the treatment is helping with a specific problem. Those answers can differ without either observation being false.

I would resist calling a higher result a success before returning to the original reason for seeking care. If the goal was less fatigue, better sleep or easier physical activity, describe what happened to that goal. A favorable-looking graph should prompt a conversation, not end it. This article looks at the awkward middle ground in which the test changes but the everyday result is unclear.

First make sure the two reports are comparable

IGF-1 testing helps evaluate growth-hormone conditions, and results need interpretation alongside age and medical circumstances. A low result can have explanations other than growth hormone deficiency; further evaluation may be necessary. ^[1]

Laboratory method also matters. A study comparing six IGF-I immunoassays found differences in reference intervals and in the classification of results. That is a reason to bring the complete reports, including their own reference ranges, rather than comparing isolated numbers from two laboratories. ^[2]

Write down the date, laboratory, reported value, units and reference interval for each result. Do not convert that record into a self-selected target. If the testing method changed, ask the ordering clinician whether the apparent difference is interpretable and whether a repeat would change any decision. Our article on assay disagreement explains why a number can look more precise than the comparison really is.

Use three separate columns at the follow-up

FDA distinguishes a biomarker from an outcome describing how someone feels, functions or survives. A surrogate endpoint can replace an outcome only when evidence supports that use in the relevant context. ^[3]

The columns are deliberately separate. A person might report feeling better while a test remains stable, or see a laboratory response without noticing a practical improvement. Neither pattern should be forced into a simple success/failure label by a review website. Ask the clinician how each observation influences the plan and what competing explanations remain plausible.

A trial in older men illustrates the measurement gap

In a trial involving eighteen older men, resistance training improved strength. Adding recombinant human growth hormone increased IGF-I and altered body composition, but did not add a strength benefit. The medicine was GH, not sermorelin; the lesson is that a hormone response and a functional response are not interchangeable measurements. ^[4]

That study does not tell us what a particular sermorelin patient should expect. It does show why an advertisement cannot stop at the earliest favorable result in a chain of proposed effects. To support “stronger,” researchers need to measure strength. To support better sleep, they need an appropriate sleep outcome. A laboratory finding alone cannot complete that argument.

Our study-level explanation covers the trial’s design. The broader muscle and strength guide brings together different interventions without pretending they are head-to-head competitors.

Make an unclear result easier to discuss

Before the next appointment, write a short account of what you hoped would change and what you have actually noticed. Specific descriptions are more useful than “optimized” or “not working.” For instance, describe which activity remains difficult and whether its frequency or severity changed. Note other changes during the same period so the clinician can interpret the story in context.

Keep observations manageable. A sprawling diary can become hard to use, while one enthusiastic day may not represent the whole period. Ask the clinician which information would be useful to collect and how often. This is a request for a follow-up plan, not a recommendation to run home experiments or change a prescription.

Also ask what evidence would support continuing, reconsidering or stopping. There may not be a clean answer at one visit. The useful outcome is a shared understanding of the next decision and who will make it. Put that question into the consultation brief alongside the complete laboratory reports.

The service should explain the result before the renewal

When reading a provider review, I give more weight to a clearly described follow-up arrangement than to a promise of “optimal” levels. Find out who interprets results, whether a conversation is included, how additional tests are billed and what happens when the clinician wants to change course. Those are concrete service questions even when the medical decision remains individualized.

The Hone Health review and our provider notebook can help you compare published service details. Use the quote comparison for financial assumptions, keeping unknown charges marked as unknown. Do not let the date of an automatic renewal become the date at which a laboratory result is declared a benefit.

A useful final question is: “If we did not have this number, what evidence would tell us my original problem had improved?” The answer need not discount laboratory monitoring. It restores the connection between monitoring and the reason treatment was considered in the first place.